West Pharmaceutical Services Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 6/6
West Pharmaceutical Services hat ein Gesamteigenkapital von $2.7B und eine Gesamtverschuldung von $206.2M, wodurch sich der Verschuldungsgrad auf 7.7% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $3.6B bzw. $921.7M. West Pharmaceutical Services Das EBIT des Unternehmens beträgt $668.3M, so dass der Zinsdeckungsgrad -31.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $601.8M.
Wichtige Informationen
8.0%
Verhältnis von Schulden zu Eigenkapital
US$205.80m
Verschuldung
| Zinsdeckungsgrad | -28.8x |
| Bargeld | US$446.20m |
| Eigenkapital | US$2.58b |
| Gesamtverbindlichkeiten | US$912.60m |
| Gesamtvermögen | US$3.49b |
Jüngste Berichte zur Finanzlage
We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27
Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31Recent updates
Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29West Pharmaceutical Q3 2022 Earnings Preview
Oct 26West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Oct 25West Pharmaceutical Services: Shares Need To Get Cheaper To Make Sense
Oct 02Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: WSTDie kurzfristigen Aktiva des Unternehmens ($1.7B) übersteigen seine kurzfristigen Passiva ($648.4M).
Langfristige Verbindlichkeiten: WSTDie kurzfristigen Vermögenswerte des Unternehmens ($1.7B) übersteigen seine langfristigen Verbindlichkeiten ($273.3M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: WST über mehr Barmittel verfügt als seine Gesamtverschuldung.
Schulden abbauen: WST Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 14.3% auf 7.7% zurückgegangen.
Schuldendeckung: WSTDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (366.9%).
Zinsdeckung: WST mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.